Bone Biologics Corp
BBLG1.930USD
+0.160+8.99%
Close 12/05, 16:00（ET）Quotes delayed by 15 min
3.46MMarket Cap
LossP/E TTM
More Details of Bone Biologics Corp Company
Bone Biologics Corporation is a developer of orthobiologic products for spine fusion markets. It is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. It is a medical device company that is focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with demineralized bone matrix (DBM), is an osteopromotive recombinant protein that provides target specific control over bone regeneration. Its platform technology is its NELL-1, a proprietary skeletal specific growth factor which is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
Bone Biologics Corp Info
Ticker SymbolBBLG
Company nameBone Biologics Corp
IPO dateNov 27, 2015
CEOMr. Jeffrey Frelick
Number of employees2
Security typeOrdinary Share
Fiscal year-endNov 27
Address2 Burlington Woods Dr Ste 100
CityBURLINGTON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code01803-4551
Phone17815524452
Websitehttps://www.bonebiologics.com/
Ticker SymbolBBLG
IPO dateNov 27, 2015
CEOMr. Jeffrey Frelick
Company Executives of Bone Biologics Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Jeffrey Frelick
Mr. Jeffrey Frelick
President, Chief Executive Officer
President, Chief Executive Officer
359.00
+0.84%
Ms. Deina H. Walsh, CPA
Ms. Deina H. Walsh, CPA
Chief Financial Officer
Chief Financial Officer
313.00
--
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
--
--
Mr. Bruce Stroever
Mr. Bruce Stroever
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Jody Cain
Mr. Jody Cain
Investor Relation
Investor Relation
--
--
Mr. Phillip T. Meikle
Mr. Phillip T. Meikle
Independent Director
Independent Director
--
--
Dr. Siddhesh Rajendra (Sid) Angle, Ph.D.
Dr. Siddhesh Rajendra (Sid) Angle, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jeffrey Frelick
Mr. Jeffrey Frelick
President, Chief Executive Officer
President, Chief Executive Officer
359.00
+0.84%
Ms. Deina H. Walsh, CPA
Ms. Deina H. Walsh, CPA
Chief Financial Officer
Chief Financial Officer
313.00
--
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
--
--
Mr. Bruce Stroever
Mr. Bruce Stroever
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Jody Cain
Mr. Jody Cain
Investor Relation
Investor Relation
--
--
Mr. Phillip T. Meikle
Mr. Phillip T. Meikle
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
DRW Securities, LLC
0.61%
Tower Research Capital LLC
0.08%
Frelick (Jeffrey)
0.02%
Walsh (Deina H)
0.02%
SBI Securities Co., Ltd.
0.01%
Other
99.25%
Shareholders
Shareholders
Proportion
DRW Securities, LLC
0.61%
Tower Research Capital LLC
0.08%
Frelick (Jeffrey)
0.02%
Walsh (Deina H)
0.02%
SBI Securities Co., Ltd.
0.01%
Other
99.25%
Shareholder Types
Shareholders
Proportion
Investment Advisor
0.63%
Hedge Fund
0.08%
Individual Investor
0.04%
Research Firm
0.03%
Other
99.22%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
21
2.33K
0.13%
-27.53K
2025Q2
26
151.13K
9.41%
+115.08K
2025Q1
27
6.66K
1.22%
-34.55K
2024Q4
36
139.64K
4.27%
-177.16K
2024Q3
35
174.78K
6.98%
-106.17K
2024Q2
34
138.99K
16.02%
-43.94K
2024Q1
34
123.42K
15.56%
-19.42K
2023Q4
32
43.06K
6.51%
-99.40K
2023Q3
31
101.95K
29.59%
-11.73K
2023Q2
29
107.23K
61.29%
+36.20K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Tower Research Capital LLC
200.00
0.01%
-104.00
-34.21%
Jun 30, 2025
Frelick (Jeffrey)
359.00
0.02%
+3.00
+0.84%
Apr 11, 2025
Walsh (Deina H)
313.00
0.02%
--
--
Apr 11, 2025
SBI Securities Co., Ltd.
--
0%
--
--
Dec 31, 2024
Clear Street LLC
138.00
0.01%
+138.00
--
Jun 30, 2025
UBS Financial Services, Inc.
113.00
0.01%
+113.00
--
Jun 30, 2025
BofA Global Research (US)
4.00
0%
--
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 18, 2023
Merger
8→1
Dec 18, 2023
Merger
8→1
Dec 18, 2023
Merger
8→1
Dec 18, 2023
Merger
8→1
Jun 06, 2023
Merger
30→1
Jun 06, 2023
Merger
30→1
Date
Type
Ratio
Dec 18, 2023
Merger
8→1
Dec 18, 2023
Merger
8→1
Dec 18, 2023
Merger
8→1
Dec 18, 2023
Merger
8→1
Jun 06, 2023
Merger
30→1
Jun 06, 2023
Merger
30→1
Jun 06, 2023
Merger
30→1
Jun 06, 2023
Merger
30→1
FAQs
Who are the top five shareholders of Bone Biologics Corp?
The top five shareholders of Bone Biologics Corp are:
Tower Research Capital LLC holds 200.00 shares, accounting for 0.01% of the total shares.
Frelick (Jeffrey) holds 359.00 shares, accounting for 0.02% of the total shares.
Walsh (Deina H) holds 313.00 shares, accounting for 0.02% of the total shares.
SBI Securities Co., Ltd. holds 0.00 shares, accounting for 0.00% of the total shares.
Clear Street LLC holds 138.00 shares, accounting for 0.01% of the total shares.
Tower Research Capital LLC holds 200.00 shares, accounting for 0.01% of the total shares.
Frelick (Jeffrey) holds 359.00 shares, accounting for 0.02% of the total shares.
Walsh (Deina H) holds 313.00 shares, accounting for 0.02% of the total shares.
SBI Securities Co., Ltd. holds 0.00 shares, accounting for 0.00% of the total shares.
Clear Street LLC holds 138.00 shares, accounting for 0.01% of the total shares.
What are the top three shareholder types of Bone Biologics Corp?
The top three shareholder types of Bone Biologics Corp are:
DRW Securities, LLC
Tower Research Capital LLC
Frelick (Jeffrey)
DRW Securities, LLC
Tower Research Capital LLC
Frelick (Jeffrey)
How many institutions hold shares of Bone Biologics Corp (BBLG)?
As of 2025Q3, 21 institutions hold shares of Bone Biologics Corp, with a combined market value of approximately 2.33K, accounting for 0.13% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -9.28%.
What is the biggest source of revenue for Bone Biologics Corp?
In --, the -- business generated the highest revenue for Bone Biologics Corp, amounting to -- and accounting for --% of total revenue.
